Join

Compare · ARAY vs DXCM

ARAY vs DXCM

Side-by-side comparison of Accuray Incorporated (ARAY) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ARAY and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
  • DXCM is the larger of the two at $23.67B, about 427.0x ARAY ($55.4M).
  • Over the past year, ARAY is down 65.8% and DXCM is down 24.8% - DXCM leads by 41.0 points.
  • Both names hit the wire about 8 times in the past 4 weeks.
  • DXCM has more recent analyst coverage (25 ratings vs 3 for ARAY).
PerformanceARAY-65.82%DXCM-24.81%
2025-05-02+0.00%2026-05-01
MetricARAYDXCM
Company
Accuray Incorporated
DexCom Inc.
Price
$0.47+0.71%
$61.33+3.02%
Market cap
$55.4M
$23.67B
1M return
+19.77%
-1.65%
1Y return
-65.82%
-24.81%
Industry
Medical/Dental Instruments
Medical/Dental Instruments
Exchange
NASDAQ
NASDAQ
IPO
2007
2005
News (4w)
8
8
Recent ratings
3
25
ARAY

Accuray Incorporated

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.

DXCM

DexCom Inc.

DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.